Eli Lilly announced that retatrutide, an experimental injectable medication, produced dramatic weight loss results in trial participants. People receiving the drug lost an average of 28 percent of their body weight over 80 weeks, according to the pharmaceutical company's data.
Retatrutide belongs to a new class of drugs that work differently from existing weight loss medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound). The drug targets three hormone pathways in the body rather than two, which researchers believe explains its stronger effect.
The 28 percent weight loss figure represents a substantial improvement over current options. For comparison, tirzepatide users typically lose 20-22 percent of their body weight at the highest doses. A person weighing 250 pounds could lose approximately 70 pounds with retatrutide, based on Eli Lilly's reported outcomes.
The trial results position retatrutide as a potential next-generation treatment for obesity, a condition affecting over 40 percent of American adults. Obesity increases risks for heart disease, type 2 diabetes, and certain cancers. Effective pharmaceutical treatments remain limited despite the scale of the health burden.
Eli Lilly is advancing retatrutide through regulatory review processes. The FDA will evaluate the drug's safety profile and efficacy data before making approval decisions. Common side effects of similar medications include nausea, vomiting, and gastrointestinal issues, though Eli Lilly has not yet detailed retatrutide's adverse event profile from these trials.
Weight loss drugs work by reducing appetite and increasing feelings of fullness. Retatrutide's triple-action mechanism may explain both its effectiveness and potential for side effects. Patients typically require ongoing injections to maintain weight loss, as stopping the medication often leads to weight